(Circulation. 2003;108:II-341.)
© 2003 American Heart Association, Inc.
Myocardial Protection and Vascular Biology |
From the Division of Cardiothoracic Surgery, Department of Physiology & Biophysics, Institute for Molecular Cardiology, and Department of Biomedical Engineering4 at the State University of New York at Stony Brook, Stony Brook, NY, USA.
Correspondence to Irvin B. Krukenkamp, MD, Professor of Surgery, Physiology and Biophysics, Chief, Cardiothoracic Surgery, State University of New York at Stony Brook, T19080 Health Science Center, Stony Brook, NY 11794-8191. Phone: 631-444-1820; Fax: 631-444-8963; E-mail: ibkmd{at}hotmail.com
| Abstract |
|---|
|
|
|---|
Methods and Results Using a Langendorff preparation, one group of isolated rabbit hearts were exposed to ischemic preconditioning (IPC) via 2 episodes of flow interruption. The second group of hearts was preconditioned with 2 episodes of either the metabolic inhibitor, sodium cyanide (NaCN), or the mitoKATP channel opener, diazoxide. The third group of hearts was exposed to the mitoKATP channel inhibitor, 5-hydroxydecanoic acid (5-HD) prior to preconditioning with NaCN, diazoxide or IPC. Controls had no drug infused. Then, ischemia was induced in all hearts by left anterior descending coronary artery occlusion and infarct size was determined. Compared with controls (40±3%), infarct size was significantly reduced in hearts preconditioned with NaCN, diazoxide or IPC (18±3%, 26±3%, 21±2%, respectively; P<0.05 versus control). These reductions were reversed by 5-HD (36±3%, 33±2%, 37±2%; NaCN, diazoxide, IPC, respectively). Secondly, whole cell patch clamped isolated guinea pig ventricular myocytes were preconditioned with 2 episodes of either NaCN or diazoxide followed by Tyrodes perfusion with membrane potential set to -70 mV. Control cells were exposed to Tyrodes solution. All cells were then clamped to -20 mV and exposed to NaCN, which caused induction of an outward potassium current. Compared with controls, the average time to induction of the outward current was significantly reduced in cells preconditioned with either brief application of NaCN (11.6±1.8 versus 5.1±1.0 minutes, control versus NaCN, P<0.05) or diazoxide (5.5±1.4 versus 2.0±0.8 minutes, control versus diazoxide, P<0.05).
Conclusion Preconditioning protects the heart through mitoKATP. This protection also alters a surface membrane current, which may be important in myocardial protection.
Key Words: metabolic inhibition mitochondrial KATP channel ischemia
| Introduction |
|---|
|
|
|---|
The blockade of oxidative phosphorylation yields decreased ATP production and thereby may activate the mitochondrial KATP current. This current is also increased by mitochondrial KATP channel openers.10,11 Opening of mitochondrial KATP channels may play a key role in myoprotection, as opening of these channels during ischemia is a turning point of self-protection against ischemic insult in myocytes. Based on these observations, we hypothesized that both metabolic inhibition and mitochondrial KATP channel openers protect both the whole organ and the isolated cell from ischemia.
This study consisted of 2 approaches: a whole organ model and an isolated cell model. The isolated cell model has the advantage that the simulated ischemia occurs after cell isolation, and so changes inherent to the cell isolation precede the ischemic insult. This model also allows for determination of changes that occur during ischemia. The whole organ model, on the other hand, allows for conventional mechanical function and infarct size measurements (which require a reperfusion phase) in response to clinically relevant ischemia and reperfusion conditions. The use of both models facilitates confirmation of findings and bridges the gap to future large animal and clinical investigations.
| Materials and Methods |
|---|
|
|
|---|
Chemicals
Diazoxide was dissolved in DMSO before addition to experimental solutions with a final concentration of DMSO less than 0.1%. Sodium cyanide (NaCN), diazoxide, 5-hydroxydecanoic acid (5-HD) and collagenase (type II) were obtained from Sigma Chemical (St. Louis, MO).
Langendorff Method (isolated whole organ study)
Adult male New Zealand white rabbits (2.8 to 3.0 kg) were anesthetized with pentobarbital (30 mg/kg) and anticoagulated with 1000 U sodium heparin. The heart was rapidly excised, the aorta was cannulated and then mounted on the Langendorff apparatus. The heart was then perfused with oxygenated (95% O2/5% CO2) Krebs solution (in mM: Na+ 135, K+ 4.7, Ca2+ 1.7, PO43- 1.1, Mg2+ 1.2, HCO3- 25, glucose 11.5, pyruvate 4.9, and Fumarate 5.4) at 37°C. The perfusion pressure was maintained at 85 mm Hg throughout the experiments.
The heart was permitted to equilibrate for 15 minutes. During that period, a small latex balloon was placed through the mitral valve into the left ventricle. Balloon pressure was monitored continuously with an indwelling catheter probe (Millar Instruments Inc); initial end-diastolic pressure was set to 5 to 10 mm Hg by water inflation. The balloon volume was then kept constant. End-systolic pressure and end-diastolic pressure were measured directly from the balloon pressure tracings, and peak developed pressure was calculated as the difference between end-systolic pressure and end-diastolic pressure for each beat. The heart was paced at 150 bpm with an asynchronous pacemaker (model 5880A, Medtronic Inc). Coronary flow (CF) was measured directly by timed collection of Krebs effluent.
Six hearts were exposed to 2 cycles of 5 minutes of global ischemia followed by 5 minutes of reperfusion (IPC). Another 6 hearts were exposed to 2 cycles of infusion with sodium cyanide (2 mmol/L), a metabolic inhibitor, for 5 minutes followed by 5 minutes of washout (NaCN). Diazoxide treated hearts (n=6) were exposed to 2 cycles of infusion with diazoxide (100 µmol/L), a mitoKATP channel opener, for 5 minutes followed by 5 minutes of washout.
To confirm the role of the mitoKATP channel, hearts were pretreated with 5-HD (200 µmol/L), a mitochondrial KATP channel blocker, for 10 minutes before IPC (IPC+5-HD; n=5), NaCN infusion (NaCN+5-HD; n=6), and diazoxide infusion (diazoxide+5-HD; n=4). The exposure of 5-HD continued until regional ischemia was subjected. Control hearts had no drug infused. All hearts were then subjected to regional ischemia by snaring a 3 to 0 silk tie that encircled the left anterior descending coronary artery (LAD), which led to a total occlusion of the LAD. Ischemia was confirmed by reduction of coronary flow. At the end of 60 minutes of ischemia, reperfusion (120 minutes) was achieved by releasing the snare. At the completion of the experiment protocol, the heart was removed from the perfusion apparatus, the ligature resnared, and 2 mL of phthalocyanine blue (Engelhard Corp., Louisville, KY) was infused through the aortic cannula. The left ventricle was sectioned horizontally into 5 to 7 slices. Both sides of each cross-section of the unstained area were scanned (Sigma Scan Pro, Version 4.01, Jandel Scientific, Scan Rafael, CA) into a personal computer (Dell Corp., Austin, TX) and represented the area at risk. The slices were then incubated in triphenyl-tetrazolium chloride (Sigma Chemical Co., St. Louis, MO) at 37°C for 20 minutes and the unstained white area was defined as the infarct region. This area was determined for both sides of each slice. Overall infarct area was computed as a weighted average of the slice by mass, and expressed as a percentage of area at risk.12
Single Guinea Pig Cell Method
Single cardiac myocytes were enzymatically isolated from adult male guinea pig hearts as described in Gao et al13 Guinea pigs, weighing 300 to 500 g, were sacrificed with sodium pentobarbital solution (1 mL of 390 mg / ml) by peritoneal injection. The heart was isolated and placed in Ca2+ free Tyrode solution and the aorta was cannulated. The heart was perfused with 50 mL of Ca2+ free Tyrode solution followed by 100 mL of Tyrode solution with 30 µmol/L CaCl2 and 0.4 mg/mL collagenase kept at 37°C. The heart was then placed in Ca2+ free Tyrode solution at room temperature for 2 hours. Afterward, a piece of the ventricle is dissected out and teased into smaller pieces in Kraft-Brühe (KB) solution containing (in mM, KCl 83; K2HPO4 30; MgSO4 5; Na-Pyruvic Acid 5; ß-OH-Butyric Acid 5; Creatine 5; Taurine 20; Glucose 10; EGTA 0.5; KOH 2; Na2-ATP 5; pH=7.2). The dissociated cells are then kept in KB solution at room temperature for at least 1 hour before the experiment. All solutions are bubbled with 100% O2. The isolated cells were stored in KB solution.
An Axopatch 1A amplifier (Axon Instruments, Inc) and the patch clamp technique were employed to observe cell membrane current. Patch-pipette resistances were 2 to 3 mol/L
before sealing. The pipette solution contained (in mM): K-Aspartic Acid 125; KCl 15; KOH 10; MgCl2 1; HEPES 10; EGTA 11; Mg-ATP 1; pH=7.2. The external Tyrode solution contained (in mM): NaCl 137.7; NaOH 2.3; KCl 4; MgCl2 1; HEPES 5; CaCl2 1; CdCl2 1; Glucose 10; pH=7.4. Under these conditions, the L-type Ca2+-current, the Na+/Ca2+ exchange current, and the Na+/K+ pump current are blocked.
Cells were held at -70 mV and exposed to two 3-minute applications of 2 mmol/L NaCN (n=4) interspersed with 3 minutes of normal Tyrode solution. Cells from the same hearts were also held at -70 mV for 12 minutes and served as control cells (n=4). Another group of cells were also held at -70 mV and exposed to 2 three-minute applications of 100 µmol/L diazoxide (n=4) interspersed with three minutes of normal Tyrode solution. Again, control cells (n=4) isolated from the same hearts were held at -70 mV membrane potential for 12 minutes. After the preconditioning treatment, the cells were held at -20 mV to measure the membrane current change induced by a longer period of metabolic inhibition (MI). After the membrane current reached equilibrium, MI was achieved by application of 2 mmol/L NaCN and zero glucose (to the external solution), to mimic ischemia. All experiments were carried out at room temperature (24±0.5°C). Both NaCN and diazoxide were dissolved in Tyrode solution and prepared at target concentrations. All patch clamp data were digitized by the data acquisition program pClamp7 (Axon Instruments, Inc) for later analysis.
Statistical Analysis
All data are presented as mean±SEM. Comparisons between groups were made with ANOVA (Systat v5.02. Systat, Inc, Evanston, IL). As indicated, multiple comparisons were made with the post hoc test. Statistical significance was considered at P<0.05.
| Results |
|---|
|
|
|---|
Left Ventricle Pressures
The brief infusion of NaCN significantly increased end diastolic pressure compared with control (7.4±1.3 versus 27.6±4.4 mm Hg, control versus NaCN, P<0.05). The brief infusion of diazoxide did not induce a change in end diastolic pressure, nor was a change observed with 5-HD pretreatment. There were no significant differences between groups during the regional ischemia and reperfusion phase. The peak developed pressure in all groups decreased during the regional ischemia and recovered slightly during the reperfusion phase. There were no significant differences between groups during the reperfusion phase.
Infarct Size
Infarct sizes for control, IPC, NaCN, and NaCN +5-HD are expressed as a percentage of the region at risk (Figure 1, Panel A). Control hearts had an infarct size of 40±3%. IPC significantly reduced infarct size to 21±2% (P<0.05 versus control). Preconditioning via metabolic inhibition with NaCN also significantly reduced infarct size (18±3%; P<0.05 versus control). However, mitoKATP channel blocked by 5-HD prior to preconditioning with NaCN reversed infarct size comparable to those in hearts not preconditioned (36±3%; P<0.05 versus NaCN).
|
Infarct sizes for control, IPC, diazoxide, diazoxide +5HD and IPC +5-HD are shown in Figure 1, Panel B. Preconditioning with the mitoKATP channel opener, diazoxide significantly reduced infarct size to 26±3% (P<0.05 versus control). These preconditioning effects were reduced by pretreatment with the mitoKATP channel inhibitor, 5-HD (33±2%; P<0.05 versus diazoxide). 5-HD pretreatment also abolished the infarct size limiting effect of IPC (37±2%; P<0.05 versus IPC).
Sarcolemmal Membrane Current Induced by NaCN Pretreated Myocyte
The Time Course of Appearance of Outward Current
Representative data are shown in Figure 2 (Panels A and B) for control and NaCN pretreated myocytes isolated from the same guinea pig heart. The membrane voltage, which is set by the user, is at the top of panel A and B, and the corresponding measured current is plotted below. In the control cell (Figure 2, Panel A), a rapid increase in the outward current induced by exposure to NaCN appears after 12.5 minutes. In the cell exposed to 2 episodes of NaCN during the pretreatment phase a decrease in the time to activation of the outward current induced by NaCN exposure is observed (Figure 2, Panel B). The average time (Figure 2, Panel C) to induction of an outward current was significantly shorter in the NaCN treated cells (5.1±1.0 minutes; P<0.05) compared with the control cells (11.6±1.8 minutes,). Figure 3 panel A and B are sample recordings demonstrating the marked reduction in time to outward current from 6.5 minutes to 2 minutes. in response to pretreatment of diazoxide. Brief exposure of diazoxide followed by metabolic inhibition induced by application of NaCN also markedly reduced the average time (Figure 3, Panel C) to activation of the outward current (5.5±1.4 minutes versus 2.0±0.8 minutes; control versus diazoxide pretreatment; P<0.05). Representative data are shown in Figure 3 (Panels A and B) for a control and a diazoxide pretreated myocyte isolated from the same heart.
|
|
| Discussion |
|---|
|
|
|---|
The Opening of Mitochondrial KATP Channels is Myoprotective
Sodium cyanide uncouples oxidative phosphorylation leading to a decrease in cellular ATP levels, which may result in opening mitochondrial KATP channels. Therefore, it is not unreasonable to presume that both sodium cyanide and the mitochondrial KATP channel opener diazoxide may exert their preconditioning effects through similar mechanisms. Herein, both agents were shown to reduce infarct size, the standard measurement for determining the effectiveness of preconditioning, and these reductions were reversed by 5-hydroxy decanoic acid, which is a mitoKATP channel blocker.
The depressed high-energy phosphate levels has been suggested to be a determinant of myocardial ischemic injury and that their improvement could result in the protection of the ischemic heart.14 Also, the preconditioned heart can preserve high-energy phosphate levels.14 However, in NaCN preconditioning, a possible explanation of our results is that the depletion of high energy phosphate caused by ischemia was altered by NaCN pretreatment. It is conceivable that the more rapid depletion of high-energy phosphate caused by NaCN preconditioning in face of the subsequent ischemic insult leads to more rapid activation of mitoKATP channels, which may be myoprotective.
Early Appearance of Sarcolemmal Outward Current Initiated by NaCN Preconditioning as Well as Diazoxide Preconditioning May Be Myoprotective
Other studies have demonstrated the application of sodium cyanide induces an outward current, which occurs with a variable time delay of roughly 2 to 20 minutes.15,16 Preconditioning is thought to decrease the time to induction of the outward current, as well as be a self-protective response of the myocyte to ischemia.15 In the present study, brief exposure to 2 mmol/L sodium cyanide before the subsequent simulated ischemia significantly decreased the time necessary to induce the outward current. This result suggests that a brief period of metabolic inhibition, to simulate ischemic preconditioning, is protective in our isolated cell model.
To elucidate the role of mitochondrial ATP-dependent potassium channels and their potential interaction with sarcolemmal membrane current, diazoxide, a specific mitochondrial agonist, was applied to the isolated cells. In these studies, diazoxide was applied as a pretreatment prior to NaCN application. Notably, diazoxide preconditioning resulted in an earlier appearance of sarcolemmal outward current as seen in cyanide preconditioning. These data suggest a coupling of the response in the sarcolemma to the mitochondrial stimulus.
Although our results are consistent with others15,16 in demonstrating a reduced time to the rapid activation of an outward sarcolemmal current, it is important to note that we did not measure mitochondrial current. Thus, we are not able to directly assess the role of mitochondrial KATP channel openers. However, it should be noted that in previous studies with the same protocol, the observed outward current has been assumed to be iKATP,15,16 a finding with which we disagree (17 and see next section).
Identification of Protective Sarcolemmal Outward Current
Previously, we have demonstrated17 in guinea pig ventricle myocytes, that the protective inward rectifier may not be ikATP. This conclusion is based on our finding that the amplitude and timing of appearance of the outward current is unaffected by glybenclamide, a blocker of the sarcolemmal KATP channel.17 These results are in agreement with those from other laboratories who note that this current declines on it own, even when glybenclamide is not present.18,19 The most likely possible candidates for this inwardly rectifying current is iK1, which is the major background potassium current involved in maintaining the resting potential and generating final repolarization of the action potential. Supporting the role for iK1 as the outward current, is the recent observation that preconditioning is eliminated when iK1 is knocked down with dominant negative Kir 2.1 gene.20 Purpose of this increased outward current is still unknown, although its presence helps the cell maintain a more hyperpolarized membrane potential, and thus enhance excitability.
One of the major roles of these inwardly rectifying potassium channels is to maintain the resting membrane potential of the cell. During ischemia, rapid activation of these channels can help maintain a membrane potential closer to electrochemical potassium membrane potential (Ek). Therefore, the cell can preserve excitability and limit the calcium and hydrogen influx earlier, which result in increasing cell survival. As potassium is the ion that contributes most to the resting membrane potential, by keeping the membrane potential closes to Ek (which is more negative than the resting membrane potential), the cell will maintain its excitability. We believe that control of these sarcolemmal ion currents is very important to increase the cell survival during the ischemia.
Study Limitations
A possible limitation of this study is that aerobic metabolism was blocked by NaCN, but anaerobic metabolism was not blocked. The latter might contribute a small amount of ATP generation during ischemia, but did not obviously affect our results.
A second concern is that the cell isolation may be affected by the isolation procedure. We suggest that this was not the case as cell membrane current determinations clearly discriminated between control and study cells.
Clinical Implication
Recently, "hyperpolarized" cardioplegia, usually with an ATP sensitive potassium (KATP) channel opener as an adjunct or sole arresting agent, has been shown to be superior to conventional cardioplegia.21,22 These agents should tend to keep Em more hyperpolarized during prolonged ischemia. Snabaitis et al23 used a sodium channel blocker to hyperpolarize Em and also documented significant improvements over conventional hyperkalemic cardioplegia. These data suggest that hyperpolarization during ischemia can maintain cell excitability and is therefore myoprotective. In preconditioning, quick activation of this protective current during ischemia may be one mechanism of myoprotection. If this hypothesis is correct, then combination of the protective effects of ischemic preconditioning with conventional cardioplegia may have a benefit to surgical patients.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
2. Jennings RB, Reimer KA, Hill ML et al. Total ischemia in dog hearts, in vitro. 1. Comparison of high energy phosphate production, utilization, and depletion, and of adenine nucleotide catabolism in total ischemia in vitro vs. severe ischemia in vivo. Circ Res. 1981; 49: 892900.
3. Vogel WM, Apstein CS, Briggs LL et al. Acute alterations in left ventricular diastolic chamber stiffness. Role of the "erectile" effect of coronary arterial pressure and flow in normal and damaged hearts. Circ Res. 1982; 51: 465478.
4. Ziegelstein RC, Cheng L, Capogrossi MC. Flow-dependent cytosolic acidification of vascular endothelial cells. Science. 1992; 258: 656659.
5. Eisner DA, Nichols CG, ONeill SC, et al. The effects of metabolic inhibition on intracellular calcium and pH in isolated rat ventricular cells. J Physiol. 1989; 411: 393418.
6. Auchampach JA, Gross GJ. Adenosine A 1 receptors, KATP channels, and ischemic preconditioning in dogs. Am J Physiol. 1993; 264: H1327H1336.
7. Wang Y, Kudo M, Xu M, et al. Mitochondrial K(ATP) channel as an end effector of cardioprotection during late preconditioning: triggering role of nitric oxide. J Molec Cell Cardiol. 2001; 33: 20372046.
8. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983; 305: 147148.[CrossRef][Medline] [Order article via Infotrieve]
9. Inoue I, Nagase H, Kishi K, et al. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature. 1991; 352: 244247.[CrossRef][Medline] [Order article via Infotrieve]
10. Sasaki N, Sato T, Marban E, et al. ATP consumption by uncoupled mitochondria activates sarcolemmal K(ATP) channels in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2001; 280: H1882H1888.
11. Tanno M, Miura T, Tsuchida A, et al. Contribution of both the sarcolemmal K(ATP) and mitochondrial K(ATP) channels to infarct size limitation by K(ATP) channel openers: differences from preconditioning in the role of sarcolemmal K(ATP) channels. Naunyn-Schmiedebergs Arch Pharmacol. 2001; 364: 226232.[CrossRef][Medline] [Order article via Infotrieve]
12. Matsuyama N, Leavens JE, McKinnon D, et al. Ischemic but not pharmacological preconditioning requires protein synthesis. Circulation. 2000; 102: III312III318.
13. Gao J, Mathias RT, Cohen IS, et al. Isoprenaline, Ca2+ and the Na(+)-K+ pump in guinea-pig ventricular myocytes. J Physiol. 1992; 449: 689704.
14. Kida M, Fujiwara H, Ishida M, et al. Ischemic preconditioning preserves creatine phosphate and intracellular pH. Circulation. 1991; 84: 24952503.
15. Liu Y, Gao WD, ORourke B, et al. Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Circ Res. 1996; 78: 443454.
16. Zhu Z, Li YL, Li DP, et al. Effect of anoxic preconditioning on ATP-sensitive potassium channels in guinea-pig ventricular myocytes. Pflugers Arch. 2000; 439: 808813.[CrossRef][Medline] [Order article via Infotrieve]
17. Gao J, Cohen IS, Mathias RT, et al. Metabolic inhibition by NaCN does not activate KATP current in guinea pig ventricular myocytes (abstract). Biophys J. 2001; 80: 637a.
18. Hu K, Duan D, Li GR, et al. Protein kinase C activates ATP-sensitive potassium current in human and rabbit ventricular myocytes. Circ Res. 1996; 78: 492498.
19. Thierfelder S, Doepner B, Gebhardt C, et al. ATP-sensitive K+ channels in heart muscle cells first open and subsequently close at maintained anoxia. FEBS Letters. 1994; 351: 3653369.[CrossRef][Medline] [Order article via Infotrieve]
20. Roberto JD, Carsten Z, Alina H, et al. Selective pharmacological inhibition and targeted knockdown of K+ inward rectifier channels IK1 (Kir2.1) abolish protection by ischemic preconditioning in rabbit ventricular myocytes (abstract) Suppl Circ. 2002; 106 (19): II264.
21. Maskal S, Cohen N, Hsia P, et al. Hyperpolarized cardiac arrest with a potassium-channel opener, aprikalim. J Thorac Cardiovasc Surg. 1995; 110: 10831095.
22. Kirvaitis RJ, Krukenkamp IB, Gaudette GR, et al. Phorbol-12, 13-Dibutyrate and Pinacidil Cardioplegia: novel forms of myoprotection. Circulation. 1996; 94: II381II388.
23. Snabaitis AK, Shattock MJ, Chambers DJ. Comparison of polarized and depolarized arrest in the isolated rat heart for long-term preservation. Circulation. 1997; 96: 3148156.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |